Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
International journal of molecular sciences, 24(13), 10449
This could lead to reduced demand for snacks, sweets, sugary beverages, and other foods commonly associated with indulgence and comfort eating. Shift in Consumer Preferences As users of GLP-1 medications experience less hunger and eat smaller portions, they may shift towards more nutrient-dense foods that offer better satiety per calorie, like protein-rich foods, fruits, and vegetables
Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes and metabolic dysfunction-associated steatotic liver disease
The medications further resulted in risk reductions for some infectious diseases, including bacterial infections (HR = 0.88
